Postdoctoral Fellow-MSH-13400-367
Salary: $74,692
Department: Psychiatry
Physical work location: 1468 Madison Ave. New York, NY 10029
Name PI or Supervisor: James Murrough, (212) 241-6539, james.murrough@mssm.edu
Web link to Lab: https://icahn.mssm.edu/research/depression-anxiety-center
Web link to Department: https://icahn.mssm.edu/about/departments-offices/psychiatry
Administrative Contact: Abigail Polanco, Abigail.polanco@mssm.edu
The T32 Postdoctoral Research Fellowship in Psychiatry at the Icahn School of Medicine at Mount Sinai is designed to train psychiatrists, clinically trained PhDs, psychologists, and social workers in clinical neuroscience. Fellows learn to formulate original research on etiology, pathogenesis, course, treatment, and prevention of serious mental illness, with a focus on schizophrenia and major mood disorders such as depression and bipolar disorder.
Technical Duties: (include any protocols)
Technical skills related to statistical analysis and computational methods (e.g., SPSS, R, Python, MATLAB) and project specific methods (e.g., fMRI, ECG, galvanic skin response, EMG)
Educational and other Requirements for the position:
Fellows must be a U.S. citizen or permanent resident and have completed one or more of the following:
MD, DO, or equivalent degree. An Accreditation Council of Graduate Medical Education-accredited residency program in psychiatry or related field is preferred.
A PhD in Clinical Psychology from an American Psychological Association (APA)-accredited doctoral program, and an APA-accredited clinical internship. There will also be opportunities to fulfill the licensure requirements as a psychologist during the T32 Postdoctoral Research Fellowship in Psychiatry.
Doctoral degree in a health care-related field from an accredited domestic or foreign organization.
Experience Required: Doctoral degree in a health care-related field from an accredited domestic or foreign organization.
Goals/Outcomes of the Research Project: Graduates of the program become skilled clinician-scientists, uniquely poised to bridge the gap between basic neurobiology and clinical disease. This combination is vital for advancing our understanding of the neurobiology of psychiatric disorders and for developing the highly needed disease-modifying treatments for psychiatric illnesses.